The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis

Journal of Neuro-oncology
Wei WeiZongze Guo

Abstract

The goal of this meta-analysis was to identify the temozolomide (TMZ) regimen with optimal efficacy and tolerance for treatment of recurrent high-grade glioma (HGG). The PubMed and EMBASE databases were searched from the earliest records to February 2015, which identified 33 studies with 1760 participants that met the inclusion criteria. The standard schedule and three most common dose-dense regimens of TMZ therapy for recurrent HGG were included in this meta-analysis. The schedule of 7 days on/7 days off for the treatment of grade IV gliomas was significantly superior to the standard regimen with respect to progression-free survival at 6 months (34.8 %; 95 % confidence interval (CI) 27.0-43.4 %) and 12 months (15.5 %; 95 % CI 10.7-21.8 %). For grade III gliomas, this regimen conveyed a significantly greater overall survival (OS) rate at 12 months (79.0 %; 95 % CI 56.2-91.7 %), as compared to the standard schedule. Also, the 21 days on/7 days off regimen had significantly longer OS rates at 6 months (73.6 %; 95 % CI 63.4-81.8 %) and 12 months (40.6 %; 95 % CI 32.6-48.6 %) than the standard regimen for grade IV gliomas. In addition, the standard schedule showed a significantly higher clinical benefit rate than the 7 days on/7 da...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Aug 15, 1995·American Journal of Epidemiology·G A ColditzF Mosteller
Nov 1, 1995·Glia·K H Plate, W Risau
Jan 1, 1997·Cancer Chemotherapy and Pharmacology·M BowerM H Brampton
Jul 8, 1999·Journal of Cancer Research and Clinical Oncology·F PaulsenM Bamberg
Nov 9, 2000·The New England Journal of Medicine·M EstellerJ G Herman
Apr 13, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A A BrandesS Monfardini
Apr 13, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BradaS Zaknoen
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·O L ChinotF Grisoli
Jul 5, 2001·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·M T HarrisL Cher
May 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stanton L Gerson
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Sep 10, 2003·Anti-cancer Drugs·Hjalmar KurzenThomas Möhler
Oct 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Guido BocciRobert S Kerbel
Oct 31, 2003·International Journal of Clinical Oncology·Tomokazu AokiNobuo Hashimoto
Jan 28, 2004·Cancer·Susan M ChangMichael D Prados
Jun 2, 2004·Nature Reviews. Cancer·Robert S Kerbel, Barton A Kamen
Mar 11, 2005·The New England Journal of Medicine·Roger StuppUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 11, 2005·The New England Journal of Medicine·Monika E HegiRoger Stupp
Jun 18, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wolfgang Wick, Michael Weller
Dec 17, 2005·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Shirley WongLawrence Cher
Feb 9, 2006·Current Oncology Reports·Mark R Gilbert
Aug 8, 2006·Journal of Korean Medical Science·Seung-Ho YangYong-Kil Hong
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Olivier L ChinotDominique Figarella-Branger
Jul 10, 2007·Acta Neuropathologica·David N LouisPaul Kleihues
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antje WickWolfgang Wick
Sep 6, 2007·Brain : a Journal of Neurology·Dietmar KrexUNKNOWN German Glioma Network
Sep 6, 2008·Neuro-oncology·Wolfgang WickMichael Weller
Aug 12, 2009·Journal of Neuro-oncology·A BerrocalUNKNOWN GENOM Cooperative Group
Oct 20, 2009·International Journal of Radiation Oncology, Biology, Physics·Markus WeilerWolfgang Wick
Feb 23, 2010·International Journal of Surgery·David MoherUNKNOWN PRISMA Group
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James R PerryJean-François Pouliot
Jun 10, 2011·Current Oncology·J C EasawUNKNOWN Canadian Glioblastoma Recommendations Committee
Mar 8, 2012·Journal of Neuro-oncology·Walter TaalMartin J van den Bent
Jun 12, 2012·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·Chao ChenShenhong Wu

❮ Previous
Next ❯

Citations

Nov 1, 2018·Journal of Neuro-oncology·Margriet IJzerman-KorevaarFilip Y F de Vos
Sep 27, 2018·Neurologia Medico-chirurgica·Shabierjiang JiapaerMitsutoshi Nakada
Sep 25, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Ashutosh GuptaAbhay K Pandey
Feb 3, 2021·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·T GuptaR Jalali
Mar 7, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Shalini Sundramurthi ChelliahIshwar Parhar
Jul 20, 2021·Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia·Hui YaoYulun Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.